Compared to Estimates, Halozyme Therapeutics (HALO) Q3 Earnings: A Look at Key Metrics

Halozyme Therapeutics reported Q3 2026 revenue of $492.97 million, up 39.2% year-over-year, beating consensus estimates by 2.27%. EPS of $2.39 exceeded expectations of $2.29 by 4.37%. Product sales and royalties both grew significantly, though collaboration agreement revenues declined 39% year-over-year. The stock has gained 17.7% over the past month and carries a Zacks Rank #3 (Hold) rating.